WO2007009758A3 - Composes chimiques - Google Patents

Composes chimiques Download PDF

Info

Publication number
WO2007009758A3
WO2007009758A3 PCT/EP2006/007080 EP2006007080W WO2007009758A3 WO 2007009758 A3 WO2007009758 A3 WO 2007009758A3 EP 2006007080 W EP2006007080 W EP 2006007080W WO 2007009758 A3 WO2007009758 A3 WO 2007009758A3
Authority
WO
WIPO (PCT)
Prior art keywords
carboxamide
piperazinyl
methylphenyl
piperidine
trifluoromethyl
Prior art date
Application number
PCT/EP2006/007080
Other languages
English (en)
Other versions
WO2007009758A2 (fr
Inventor
Silvia Martinucci
Andrew Roberts
Original Assignee
Glaxo Group Ltd
Silvia Martinucci
Andrew Roberts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd, Silvia Martinucci, Andrew Roberts filed Critical Glaxo Group Ltd
Publication of WO2007009758A2 publication Critical patent/WO2007009758A2/fr
Publication of WO2007009758A3 publication Critical patent/WO2007009758A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un composé représenté par la formule (I) ou un sel ou un solvate pharmaceutiquement acceptables de ce composé, un procédé permettant de préparer ces composés, l'utilisation de ces composés pour le traitement de maladies dont les tachykinines sont des médiateurs, et des compositions pharmaceutiques contenant ces composés.
PCT/EP2006/007080 2005-07-18 2006-07-14 Composes chimiques WO2007009758A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0514705.3 2005-07-18
GBGB0514705.3A GB0514705D0 (en) 2005-07-18 2005-07-18 Chemical compounds

Publications (2)

Publication Number Publication Date
WO2007009758A2 WO2007009758A2 (fr) 2007-01-25
WO2007009758A3 true WO2007009758A3 (fr) 2007-04-19

Family

ID=34897390

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/007080 WO2007009758A2 (fr) 2005-07-18 2006-07-14 Composes chimiques

Country Status (2)

Country Link
GB (1) GB0514705D0 (fr)
WO (1) WO2007009758A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0812849D0 (en) * 2008-07-14 2008-08-20 Glaxo Wellcome Mfg Pte Ltd Novel compounds

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002032867A1 (fr) * 2000-10-17 2002-04-25 Glaxo Group Limited Composes chimiques
WO2003066621A1 (fr) * 2002-02-08 2003-08-14 Glaxo Group Limited Derives de piperidine et leur utilisation en tant qu'antagonistes des tachykinines
WO2003099787A1 (fr) * 2002-05-29 2003-12-04 Tanabe Seiyaku Co., Ltd. Nouveau compose de piperidine
WO2004110996A1 (fr) * 2003-06-19 2004-12-23 Pfizer Products Inc. Antagoniste de nk1

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002032867A1 (fr) * 2000-10-17 2002-04-25 Glaxo Group Limited Composes chimiques
WO2003066621A1 (fr) * 2002-02-08 2003-08-14 Glaxo Group Limited Derives de piperidine et leur utilisation en tant qu'antagonistes des tachykinines
WO2003099787A1 (fr) * 2002-05-29 2003-12-04 Tanabe Seiyaku Co., Ltd. Nouveau compose de piperidine
WO2004110996A1 (fr) * 2003-06-19 2004-12-23 Pfizer Products Inc. Antagoniste de nk1

Also Published As

Publication number Publication date
WO2007009758A2 (fr) 2007-01-25
GB0514705D0 (en) 2005-08-24

Similar Documents

Publication Publication Date Title
EP2286825A3 (fr) Ligands des récépteurs de la mélanocortine
WO2007106181A3 (fr) Antagonistes des récepteurs du glucagon, leur préparation et leurs utilisations thérapeutiques
WO2007120270A3 (fr) Antagonistes de récepteur du glucagon, procédés de préparation et utilisations thérapeutiques
WO2007120284A3 (fr) Antagonistes de récepteur du glucagon, procédés de préparation et utilisations thérapeutiques
EP1741712A3 (fr) Nebivolol et son sels pharmaceutiques acceptables, procès pour la preparation et compositions pharmaceutiques de nebivolol
EA200970585A1 (ru) Бензамидные производные как агонисты ер-рецепторов
PL1735278T3 (pl) Związki receptora histaminowego H3, wytwarzanie i zastosowania terapeutyczne
WO2005094810A3 (fr) Nouvelles compositions pharmaceutiques
PL2054411T3 (pl) Nowe związki, ich izomery lub ich farmaceutycznie dopuszczalne sole jako antagoniści receptora waniloidowego oraz zawierające je kompozycje farmaceutyczne
WO2006086488A3 (fr) Antagonistes du recepteur du glucagon, leur preparation et leurs utilisations therapeutiques
MA28706B1 (fr) Antagoniste des recepteurs du glucagon, preparation et utilisations therapeutiques
EP2397476A3 (fr) Dérivé d'indole doté d'une activité antagoniste de récepteur PGD2
EA200801998A1 (ru) ПИРИДИН[3,4-b]ПИРАЗИНОНЫ
WO2006071740A3 (fr) Compositions renfermant un modulateur des recepteurs 5ht2c et procedes d'utilisation correspondants
EP1861357A4 (fr) Nouveaux composes, isomere de ceux-ci, ou sels de ceux-ci acceptables sur le plan pharmaceutique utilises en tant qu'antagonistes de recepteur vanilloide; et compositions pharmaceutiques contenant ces composes
WO2007114855A3 (fr) Antagonistes du récepteur du glucagon, préparation et utilisations thérapeutiques
WO2008121348A8 (fr) Antagonistes de récepteurs opioïdes périphériques, et leurs utilisations
EP2202222A3 (fr) Dérivés d'indène, leur préparation et leur utilisation en tant que médicaments
WO2005082893A3 (fr) Antagonistes du recepteur d'histamine h3, leur preparation et leurs utilisations therapeutiques
NO20071314L (no) Peptidiske vasopressinreseptoragonister
MY145919A (en) Pharmaceutical formulation comprising neurokinin antagonist
MX2009006010A (es) Derivados de amina y su uso en enfermedades mediadas por el adrenoreceptor beta 2.
NO20060191L (no) 1-(alkylaminoalkyl-pyrolidin-/piperidinyl)2,2-difenylacetamidderivater som muskarinreceptoragonister
WO2009032843A3 (fr) Aminoalcools substitués
PT1861360E (pt) Derivados de pirrolidina como antagonistas de receptores h3 de histamina

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06762682

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 06762682

Country of ref document: EP

Kind code of ref document: A2